Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor

Cancer Biomarkers

Volumn 6, Issue 2, 2009, Pages 73-82

  Callesen, Anne K ^a   Madsen, Jonna S ^b   Iachina, Maria ^a   Vach, Werner ^a,c   Kruse, Torben A ^d   Jensen, Ole N ^a   Mogensen, Ole ^d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

MALDI TOF MS; ovarian cancer; Protein profiling; proteomics; serum

Indexed keywords

CA 125 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CYSTADENOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROMA; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; OVARY CANCER; OVARY CYST; OVARY TERATOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PEPTIDES; PROTEIN ARRAY ANALYSIS; PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77954121248     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2009-0120     Document Type: Article

References (34)

1. R.C. Bast, Jr., D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K.A. Baggerly, E.N. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs and K. Lu, New tumor markers: CA125 and beyond, Int J Gynecol Cancer 15 (2005), 274-281.
2. W. Hamilton, A. Round and D. Sharp, Ovarian cancer. Not a silent killer, BMJ 339 (2009), b2719.
3. E.I. Garner, Advances in the early detection of ovarian carcinoma, J Reprod Med 50 (2005), 447-453.
4. E.C. Kohn, N. Azad, C. Annunziata, A.S. Dhamoon and G. Whiteley, Proteomics as a tool for biomarker discovery, Dis Markers 23 (2007), 411-417.
5. R.B. Dann, J.L. Kelley and K.K. Zorn, Strategies for Ovarian Cancer Prevention, Obstet Gynecol Clin N Am 34 (2007), 667-686.
6. S. Risum, C. Høgdall, A. Loft, A.K. Berthelsen, E. Høgdall, L. Nedergaard, L. Lundwall and S.A. Engelholm, The diagnostic value of PET/CT for primary ovarian cancer - A prospective study, Gynecol Oncol 105 (2007), 145-149. (Pubitemid 46454333)
7. S. Risum, C. Høgdall, A. Loft, A.K. Berthelsen, E. Høgdall, L. Nedergaard, L. Lundwall and S.A. Engelholm, Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - A prospective study, Gynecol Oncol 108 (2008), 265-270.
8. S. Basu, G. Li and A. Alavi, PET and PET-CT imaging of gynecological malignancies: present role and future promise, Expert Rev Anticancer Ther 9 (2009), 75-96.
9. U. Menon, A. Gentry-Maharaj, R. Hallett, A. Ryan, M. Burnell, A. Sharma, S. Lewis, S. Davies, S. Philpott, A. Lopes, K. Godfrey, D. Oram, J. Herod, K. Williamson, M.W. Seif, I. Scott, T. Mould, R. Woolas, J. Murdoch, S. Dobbs, N.N. Amso, S. Leeson, D. Cruickshank, A. McGuire, S. Campbell, L. Fallowfield, N. Singh, A. Dawnay, S.J. Skates, M. Parmar and I. Jacobs, Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Lancet Oncol 4 (2009), 327-340.
10. A.B. Joyner and C.D. Runowicz, Ovarian cancer screening and early detection, Womens Health (Lond Engl) 5 (2009), 693-699.
11. D. Badgwell and R.C. Bast, Jr., Early detection of ovarian cancer, Dis Markers 23 (2007), 397-410.
12. A. Mano, A. Falcao, I. Godinho, J. Santos, F. Leitao, C. de Oliveira and M. Caramona, CA-125 AUC as a predictor for epithelial ovarian cancer relapse, Cancer Biomark 4 (2008), 73-81.
13. G.J. Rustin, R.C. Bast Jr, G.J.Kelloff, J.C. Barrett, S.K. Carter, P.D. Nisen, C.C. Sigman, D.R. Parkinson and R.W. Ruddon, Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer, Clin Cancer Res 10 (2004), 3919-3926.
14. A.E. Guppy and G.J. Rustin, CA125 Response: Can it replace the Traditional Response Criteria in Ovarian Cancer? Oncologist 7 (2002), 437-443.
15. E.M. Posadas, F. Simpkins, L.A. Liotta, C. MacDonald and E.C. Kohn, Proteomic analysis for the early detection and rational treatment of cancer - realistic hope? Annals of Oncology 16 (2005), 16-22.
16. E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, G.B. Mills, C. Simone, D.A. Fishman, E.C.Kohn and L.A. Liotta, Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 (2002), 572-577. (Pubitemid 34178440)
17. B.L. Adam, Y. Qu, J.W. Davis, M.D. Ward, M.A. Clements, L.H. Cazares, O.J. Semmens, P.F. Schellhammer, Y. Yasui, Z. Feng and G.L.J. Wright, Serum protein fingerprinting coupled with pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men, Cancer Res 62 (2002), 3609-3614.
18. J. Li, Z. Zhang, J. Rosenzweig, Y. Young and D. Chan, Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin Chem 48 (2002), 1296-1304.
19. A. Jurisicova, I. Jurisica and T. Kislinger, Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions, Expert Rev Proteomics 5 (2008), 551-560.
20. K.R. Kozak, M.W. Amneus, S.M. Pusey, F. Su, S.A. Luong, S.T. Reddy and R. Farias-Eisner, Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis, PNAS 100 (2003), 12343-12348.
21. H. Zhang, B. Kong, X. Qu, L. Jia, B. Deng and Q. Yang, Biomarker discovery for ovarian cancer using SELDI-TOFMS, Gynecol Oncol 102 (2006), 61-66.
22. F. Kong, N. White, X. Xiao, Y. Feng, C. Xu, D. He, Z. Zhang and Y. Yu, Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer, Gynecol Oncol 100 (2006), 247-253.
23. Lin Y.W., C.Y. Lin, H.C. Lai, J.Y. Chiou, C.C. Chang and M.H. Yu, Plasma proteomic pattern as biomarkers for ovarian cancer, Int J Gynecol Cancer 16 (2006), 139-146.
24. K.A. Baggerly, J.S. Morris and K.R. Coombes, Reproducibility of SELDI TOF protein patterns in serum: comparing data sets from different experiments, Bioinformatics 20 (2004), 777-785.
25. G.L. Hortin, The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome, Clin Chem 52 (2006), 1223-1237.
26. A.K. Callesen, R. Christensen, J.S. Madsen, W. Vach, E. Zapico, S. Cold, P.E. Jørgensen, O. Mogensen, T.A. Kruse and O.N. Jensen, Reproducibility of serum protein profiling by systematic assessment using solid phase extraction and MALDI MS, Rapid Commun Mass Spectrom 22 (2008), 291-300.
27. A.K. Callesen, W. Vach, P.E. Jørgensen, S. Cold, Q. Tan, R. Christensen, O. Mogensen, T.A. Kruse, O.N. Jensen and J.S. Madsen, Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: A case-control study, J Proteome Res 7 (2008), 1419-1426.
28. M. Karas and F. Hillenkamp, Laser desorption ionization of proteins with molecular masses exceeding 10000 Daltons, Anal Chem 60 (1988), 2299-2301.
29. P.H.Westfall and S.S.Young, Resampling-based multiple testing: Examples and methods for p-value adjustment, Wiley, New York, 1993.
30. A. Vlahou, J.O. Schorge, B.W. Gregory and R.L. Coleman, Diagnosis of Ovarian Cancer Using Decision Tree Classifi- cation of Mass Spectral Data, J Biomed Biotechnol 5 (2003), 308-314.
31. C.H. Holschneider and J.S. Berek, Ovarian cancer: epidemiology, biology, and prognostic factors, Semin Surg Oncol 19 (2000), 3-10.
32. L.P. Petri, E. Høgdall, I.J. Christensen, S.K. Kjaer, J. Blaakær and C.K. Høgdall, Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer, APMIS 114 (2006), 359-363.
33. A. Klærbye-Thygesen, L.D. Huusom, K. Frederiksen and S.K. Kjær, Trends in the incidence and mortality of ovarian cancer in Denmark 1978-2002. Comparison with other Nordic countries, Acta Obstet Gynecol Scand 84 (2005), 1006-1012.
34. P.A. Meeuwissen, C. Seynaeve, C.T. Brekelmans, H.J. Meijers-Heijboer, J.G. Klijn and C.W. Burger, Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer, Gynecol Oncol 97 (2005), 476-482.